Abstract
Bone metastases are a frequent complication of advanced cancer. Interactions between cancer cells and marrow stromal cells and bone turnover mechanisms are crucial in metastases growth and the pathogenesis of bone damage. Metastatic tumour cells stimulate the bone remodelling and indirectly induce the osteocytes to release several growth factors that promote the proliferation of stromal, haematopoietic and neoplastic cells in a sort of vicious circle. Histological examination of bone metastasis of known origin is performed usually to define prognostic and/or predictive markers for target cancer therapy; in the 10–30% of patients in which the primary tumour is not identified, the histologic findings derived from bone biopsy could be diagnostic by morphological or immunohistochemical assessment of the neoplastic tissue.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–9.
Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564–71.
Ulrich U, Rhiem K, Schmolling J, Flaskamp C, Paffenholz I, Salzer H, et al. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet. 2001;264:186–90.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69.
Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(Suppl 3):iii124–37.
Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221–7.
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
Martin RB. Does osteocyte formation cause the nonlinear refilling of osteons? Bone. 2000;26:71–8.
Robling AG, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283:5866–75.
Tu X, et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012;50:209–17.
Leupin O, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286:19489–500.
Bellido T, Plotkin LI, Bruzzaniti A. Bone cells. In: Burr D, Allen M, editors. Basic and applied bone biology. Atlanta: Elsevier; 2014. p. 27–45.
Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504–8.
Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050–5.
Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell and more. Endocr Rev. 2013;34:658–90.
Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26:229–38.
Xiong J, et al. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17:1235–41.
Nakashima T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17:1231–4.
Suva LJ. Sclerostin and the unloading of bone. J Bone Miner Res. 2009;24:1649–50.
Wijenayaka AR, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:e25900.
Compton JT, Lee FY. A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am. 2014;96:1659–68.
Zhou JZ, et al. Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene. 2015;34:1831–42.
Vandecandelaere M, Flipo RM, Cortet B, Catanzariti L, Duquesnoy B, Delcambre B. Bone metastases revealing primary tumors. Comparison of two series separated by 30 years. Joint Bone Spine. 2004;71(3):224–9.
Nottebaert M, Exner GU, von Hochstetter AR, Schreiber A. Metastatic bone disease from occult carcinoma: a profile. Int Orthop. 1989;13(2):119–23.
Cooke KS, Kirpekar M, Abiri MM, Shreefter C. US case of the day. Skeletal metastasis from poorly differentiated carcinoma of unknown origin. Radiographics. 1997;17(2):542–4.
Piccioli A. Breast cancer bone metastases: an orthopedic emergency. J Orthop Traumatol. 2014;15(2):143–4.
Katagiri H, Takahashi M, Inagaki J, Sugiura H, Ito S, Iwata H. Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study. Cancer. 1999;86(3):533–7.
Piccioli A, Capanna R. Il trattamento delle metastasi ossee. Linee Guida S.I.O.T; 2008.
Wedin R, Bauer HC, Skoog L, Söderlund V, Tani E. Cytological diagnosis of skeletal lesions. Fine-needle aspiration biopsy in 110 tumours. J Bone Joint Surg Br. 2000;82(5):673–8.
Xu DL, Zhang XT, Wang GH, Li FB, Hu JY. Clinical features of pathologically confirmed metastatic bone tumors—a report of 390 cases. Ai Zheng. 2005;24(11):1404.
Conroy T, Platini C, Troufleau P, Dartois D, Lupors IE, Malissard L, et al. Presentation clinique et facteurspronostics au diagnostic de metastases osseuses. A propos de d’uneserie de 578 observations. Bull Cancer. 1993;80:S16e22.
Papagelopoulos P, Savvidou O, Galanis E, et al. Advances and challenges in diagnosis and management of skeletal metastases. Orthopedics. 2009;29(7):609–20.
Shih LY, Chen TH, Lo WH. Skeletal metastasis from occult carcinoma. J Surg Oncol. 1992;51(2):109–13.
Airoldi G. Cancer of unknown primary origin: utility and futility in clinical practice. Ital J Med. 2012;6:315–26.
Hemminki K, Riihimäki M, Sundquist K, Hemminki A. Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer. 2013;133(1):182–9.
Bitran JD, Ultmann JE. Malignancies of undetermined primary origin. Dis Mon. 1992;38(4):213–60.
Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol. 2012;23(Suppl 10):271–7.
Simon MA, Karluk MB. Skeletal metastases of unknown origin. Diagnostic strategy for orthopedic surgeons. Clin Orthop Relat Res. 1982;166:96–103.
Acknowledgements
The authors are grateful to Dr. Martina Leopizzi for helping in building iconography and to Dr. Carmen Mazzitelli and Dr. Caterina Chiappetta for the critical review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Rocca, C.D., Di Cristofano, C. (2019). Pathology of Bone Metastasis. In: Denaro, V., Di Martino, A., Piccioli, A. (eds) Management of Bone Metastases. Springer, Cham. https://doi.org/10.1007/978-3-319-73485-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-73485-9_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-73484-2
Online ISBN: 978-3-319-73485-9
eBook Packages: MedicineMedicine (R0)